Juan Mu
Overview
Explore the profile of Juan Mu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mu J, Wang T, Ji M, Yin Q, Wang Z
J Clin Nurs
. 2024 May;
33(8):3033-3055.
PMID: 38764213
Background: The purpose of this study is to examine and evaluate the existing clinical practice guidelines and consensus statements regarding tracheostomy care for non-mechanically ventilated patients. Methods: A systematic search...
2.
Wang T, Mu J, Chen J, Lin C
Int J Nurs Stud Adv
. 2024 May;
6:100181.
PMID: 38746816
Background: The release of ChatGPT for general use in 2023 by OpenAI has significantly expanded the possible applications of generative artificial intelligence in the healthcare sector, particularly in terms of...
3.
Li J, Mu J, Wang J, Li X, Li Q, Jiang Y, et al.
Cell Transplant
. 2024 Apr;
33:9636897241247951.
PMID: 38651796
Hematological toxicity is a severe adverse event (AE) in anti-CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, the pathophysiological mechanism underlying...
4.
Jiang Y, Mu J, Cui R, Li X, Wang J, Li Q, et al.
Cancer Med
. 2024 Mar;
13(4):e7064.
PMID: 38457256
Introduction: Although anti-CD19 chimeric antigen receptor (CAR) T cell therapy was approved as a very effective salvage strategy in relapsed/refractory (R/R) B cell lymphoma, the experience in R/R gastrointestinal (GI)...
5.
Qi Y, Liu H, Li X, Shi Y, Mu J, Li J, et al.
Ann Med
. 2023 Jul;
55(1):2230888.
PMID: 37417690
Background: Anti-CD19 chimeric antigen receptors (CARs) T-cell therapy has been shown to have excellent efficacy in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL). But many patients are refractory...
6.
Ye X, Fan X, Cui R, Mu J, Liu M, Lyu C, et al.
Ann Hematol
. 2023 May;
102(7):1789-1799.
PMID: 37171599
Although anti-CD19 chimeric antigen receptor (CAR) T cell therapy has achieved satisfactory results in relapsed/refractory (R/R) follicular lymphoma (FL), patients with R/R FL and high-risk disease characteristics, previous hematopoietic stem...
7.
Ye X, Liu M, Lv C, Li Y, Chen L, Zhang J, et al.
Technol Cancer Res Treat
. 2022 Oct;
21:15330338221133224.
PMID: 36254554
Bruton's tyrosine kinase inhibitors are commonly used and effective for lymphoma and chronic lymphocytic leukemia (CLL). Ibrutinib might improve the effect of anti-cluster of differentiation 19 (CD19) chimeric antigen receptor...
8.
Mu J, Wu Y, Jiang C, Cai L, Li D, Cao J
Front Nutr
. 2022 Apr;
9:809091.
PMID: 35464000
Ovarian cancer is a malignancy that seriously endangers women's health; its case fatality rate ranks first among the gynecological malignancies. The status of nutrition of ovarian cancer patients is related...
9.
Mu J, Deng H, Lyu C, Yuan J, Li Q, Wang J, et al.
Hematol Oncol
. 2022 Feb;
41(2):275-284.
PMID: 35195933
We studied the efficacy and safety of the combined treatment with programmed cell death 1 (PD-1) inhibitors and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and subsequent PD-1 inhibitor maintenance...
10.
Lu W, Jin X, Lyu H, Bai X, Zhu H, Li X, et al.
Cell Transplant
. 2022 Feb;
31:9636897221076050.
PMID: 35168385
Effect of co-infusion third party umbilical cord blood stem cells on haploidentical hematopoietic stem cell transplantation https://www.chictr.org.cn Reg. No. ChiCTR-OIN-17011426.